# An Open-Label ProSpective MultiCENTer Study to Evaluate Safety and Tolerability of Dry Powder Inhaled Treprostinil in PH

> **NCT06129240** · — · ACTIVE_NOT_RECRUITING · sponsor: **Liquidia Technologies, Inc.** · enrollment: 80 (estimated)

## Conditions studied

- Pulmonary Hypertension
- Interstitial Lung Disease

## Interventions

- **DRUG:** LIQ861

## Key facts

- **NCT ID:** NCT06129240
- **Lead sponsor:** Liquidia Technologies, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-12-28
- **Primary completion:** 2027-07-31
- **Final completion:** 2028-02-08
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2026-02-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06129240

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06129240, "An Open-Label ProSpective MultiCENTer Study to Evaluate Safety and Tolerability of Dry Powder Inhaled Treprostinil in PH". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06129240. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*